ORPHA:562
McCune-Albright syndrome
Publications
13,496
96.8th percentile
Trials
9
Interventional, condition-specific
Researchers
966
Distinct authors in sample
Gene link
GNAS
Definitive
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare mosaic syndrome characterized by the combination of two or more of the following: fibrous of bone (FD), hyperpigmented macules, and hyperfunctioning endocrinopathies (precocious puberty, hyperthyroidism, growth hormone excess, endogenous Cushing syndrome).
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018919
- OMIM:174800
- UMLS:C0242292
- NCIT:C48627
Additional Mondo synonyms (6)
Albright's disease · MAS · McCune Albright Syndrome · McCune Albright syndrome · gonadotropin-independent female-limited sexual precocity · mccune-albright syndrome, somatic, mosaic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — GNAS
- LiteraturePresent
13,496 matched papers (9,311 in last 10 years) Source
- Phenotype characterisedPresent
74 HPO annotations (e.g. Ovarian cyst; Precocious puberty; Macroorchidism) Source
- Animal modelPresent
3 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
9 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GNAS).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
74
Associated phenotypes · MONDO:0018919
- Ovarian cyst
- Precocious puberty
- Macroorchidism
- Pancreatitis
- Nasal congestion
Showing 5 of 74 — open Monarch for the full list.
Animal models (Monarch / Alliance)
3
Model associations linked to this Mondo ID
- Tg(EEF1A1-Gnas*R201C)184Pabi/0 [background:] either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * FVB/N)·MGI:5883024·Mus musculus
- Tg(PGK1-Gnas*R201C)60Pabi/0 [background:] either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * FVB/N)·MGI:5883020·Mus musculus
- Tg(Col1a1-tTA)139Niss/0 Tg(tetO-HTR4*D100A)2Niss/0 [background:] FVB/N-Tg(Col1a1-tTA)139Niss Tg(tetO-HTR4*D100A)2Niss·MGI:5643856·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0018919
- PEGVISOMANT·phase 3
- ALENDRONIC ACID·phase 2
- FULVESTRANT·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
13,496
13,496 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
13,496 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
9,311 in the last 10 years · medium confidence · 96.8th percentile (publications denominator)
Phrase hits: 2,994 · MeSH hits: 0
Who's working on it?
966
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Boyce AM7 papers · 2026
Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
Papers in Europe PMC - 02Upadhyay J6 papers · 2026
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Papers in Europe PMC - 03Appelman-Dijkstra NM5 papers · 2026
Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Papers in Europe PMC - 04Berry C5 papers · 2026
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 05Chapurlat R5 papers · 2026
French Reference Center for Fibrous Dysplasia, Rheumatology Department, Hospital E.Herriot, Hospices Civils de Lyon, University of Lyon 1, Lyon, France.
Papers in Europe PMC - 06Javaid MK5 papers · 2026
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. kassim.javaid@ndorms.ox.ac.uk.
Papers in Europe PMC - 07Mannstadt M5 papers · 2026
Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Papers in Europe PMC - 08Peacock ZS5 papers · 2026
Department of Oral & Maxillofacial Surgery, Massachusetts General Hospital, Harvard School of Dental Medicine, Boston, MA 02114, USA.
Papers in Europe PMC - 09Li X4 papers · 2026
Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Papers in Europe PMC - 10Barlier A3 papers · 2026
Aix Marseille Univ, Assistance Publique-Hôpitaux De Marseille (APHM), Institut national de la santé et de la recherche médicale (INSERM), Marseille Medical Genetics (MMG), La Timone Hospital, Laboratory of Molecular Biology GEnOPe, Biogenopole, Marseille, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
9 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92th percentile).
medium confidence · 92th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05966064·RECRUITING·DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)
Not reviewed·Conditions: Fibrous Dysplasia · McCune Albright Syndrome·Matched via name phrase
- NCT07476768·NOT YET RECRUITING·PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study
Not reviewed·Conditions: Fibrous Dysplasia of Bone · McCune Albright Syndrome·Matched via name phrase
Observational and natural-history studies
10 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03231644·RECRUITING·Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry
Not reviewed·Conditions: Fibrous Dysplasia · McCune Albright Syndrome · Mazabraud Syndrome·Matched via name phrase
- NCT00001727·RECRUITING·Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
Not reviewed·Conditions: McCune-Albright Syndrome·Matched via name phrase
- NCT07569731·RECRUITING·Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data
Not reviewed·Conditions: Fibrous Dysplasia · Fibrous Dysplasia of Bone · Fibrous Dysplasia/McCune-Albright Syndrome · Mazabraud Syndrome·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (3)
- ctis·2024-511090-30-00·Authorised, ongoing·DEnosumab for the treatment of FIbrous Dysplasia/McCune-Albright Syndrome in adults (DeFiD): a randomized double-blind placebo-controlled trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11469487·No longer recruiting·Aromatase inhibitors in girls: Anastrozole combined to the LHRH analogue leuprorelin in Girls with early or precocious puberty and a compromised growth potential
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82088322·No longer recruiting·Study of two anti-thyroid drug treatment regimens in young people with thyrotoxicosis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for McCune-Albright syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("McCune-Albright syndrome" OR "Albright's disease" OR "McCune Albright Syndrome" OR "gonadotropin-independent female-limited sexual precocity" OR "mccune-albright syndrome, somatic, mosaic") OR ("GNAS" OR "GNAS syndrome" OR "GNAS-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"McCune-Albright syndrome" OR "Albright's disease" OR "McCune Albright Syndrome" OR "gonadotropin-independent female-limited sexual precocity" OR "mccune-albright syndrome, somatic, mosaic"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 10 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MAS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:21:08.767Z
